Phase 2 Long COVID Trial, Recruiting NCT06492798 Sponsor: Changhai Hospital Condition: Long COVID
Back to Long Covid

Phase 2 Long COVID Trial, Recruiting

NCT06492798
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Long COVID according to the World Health Organization's definition.
  • Your main symptoms have been recorded and measured using a standard medical rating system called CTCAE 5.0 (confirm with trial site).
  • A relevant specialist has checked your symptoms to rule out other possible causes or diseases.
  • You are not planning to become pregnant in the near future — women who could become pregnant must have a negative pregnancy test within 72 hours before starting the trial, and must be willing to use non-medication-based contraception throughout the study.
  • You are willing to sign a consent form agreeing to take part in this clinical trial.

Who may not be able to join:

  • You currently have an active cancer diagnosis.
  • You currently have an active infection.
  • Your liver or kidney function test results are significantly above the normal range (confirm with trial site for specific values).
  • You are currently pregnant, breastfeeding, or planning to become pregnant during the trial.
  • You have taken part in another clinical trial within the last 3 months before being assessed for this study.
  • The trial team has identified another reason they feel makes your participation unsuitable (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yuchao Dong, Doctor, Changhai Hospital

Phone: +86 021-31161314

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Changhai Hospital
Registry
ClinicalTrials.gov
Start date
1 September 2023
Est. completion
1 July 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Common Terminology Criteria for Adverse Events (CTCAE5.0)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov